R42

WiseWorks is a communications intelligence platform that enables financial institutions to derive essential insights from audio and video interactions. The platform automates the joining of records, transcription, and analysis of communications, thereby enhancing existing workflows. By providing organizations with access to relevant insights, WiseWorks helps mitigate risks associated with communication failures and inefficiencies.

Spirea Ltd. operates as a healthcare technology company that has developed a smart polymer platform for the controlled delivery of drug combinations to maximise the clinical impact of medicines.

Stamp Free Ltd. operates as a digital postage stamp company.

Oxford Drug Design focuses on developing innovative therapies to combat drug-resistant infections through advanced drug discovery techniques. The company employs a multidisciplinary research approach that integrates computational chemistry, cheminformatics, mathematics, and cloud computing to enhance the drug discovery process. Its flagship platform, DrugFinder, utilizes cutting-edge technologies to facilitate computer-aided drug discovery, covering all stages from target identification to preclinical studies. By addressing high unmet medical needs, Oxford Drug Design aims to provide healthcare professionals with effective new antibiotics for treating challenging diseases, including cancer and other conditions associated with drug resistance.

Bounce Imaging, Inc. specializes in the manufacturing of tactical throwable cameras equipped with multiple lenses and sensors, designed primarily for use by police and firefighters. The company's innovative products enable first responders to safely assess hazardous environments remotely, providing real-time video and sensor data while maintaining stability during movement. In addition to its camera systems, Bounce Imaging offers a variety of accessories, including pole attachments, tethers, car chargers, headsets, wrist straps, and magnetic mounts. The company also provides cloud-based services that encompass technical consulting, design and implementation support, and troubleshooting for imaging and processing hardware. Founded in 2012, Bounce Imaging is headquartered in Buffalo, New York.

ExSeed Health Limited, based in London, United Kingdom, specializes in home sperm testing solutions designed to assess fertility through sperm count and motility. The company offers a sperm testing device that utilizes micro-optic technology for accurate measurement of sperm quality, complemented by an intelligent lifestyle app. This app provides personalized lifestyle intervention supplements based on scientifically researched data, empowering users to enhance their reproductive health. Founded in 2017, ExSeed Health markets its products both online and in physical stores, making it accessible for individuals seeking to evaluate and improve their sperm quality in the privacy of their own homes.

Fountain Therapeutics is discovering and developing treatments for aging-associated diseases. Fountain Therapeutics was founded with the belief that a future in which we live healthier lives longer is more desirable than one in which the company continues to be afflicted by the disease of aging. The company builds a transformative model of aging that re-creates many of the complex hallmark features of aging but in a laboratory dish. We are combining this powerful cellular model with the latest in artificial intelligence and computer vision to develop a disruptive unbiased platform for the identification of novel targets and potential therapeutics.

VividQ Limited is a deep tech software company based in Cambridge, United Kingdom, specializing in 3D holography. Founded in February 2017 by a team of Ph.D. graduates, VividQ has developed a comprehensive software platform that enables the generation, compression, and transmission of 3D holographic images and video using standard computing power. Its key products include VividQ Capture, which standardizes 3D data for holographic display; VividQ Squeeze, a solution for compressing point cloud data; and VividQ Core, which facilitates multi-user interactions with holograms. The company also offers VividQ View, an API for integrating spatial light modulators into its holographic systems. VividQ's technology is applicable in a variety of fields, including augmented reality, virtual reality, automotive displays, and consumer electronics. By collaborating with chipmakers and manufacturers, VividQ aims to make holography a commercially viable display solution.

Abselion specializes in the development of biosensors aimed at enhancing the analysis of biological substances, such as proteins and small molecules, for pharmaceutical research and manufacturing. The company's innovative diagnostic analyzers and kits facilitate the study of biomolecular interactions, including protein interaction analysis. By providing a rapid and cost-effective means of detecting biological materials, Abselion enables researchers to achieve sensitive and near real-time medical diagnoses, thereby simplifying the analytical processes essential for advancing pharmaceutical research.

Developer of a cloud-based platform designed to improve cancer treatment through the prediction of patients' responses. The company's platform identifies optimal treatment for an individual, reduces treatment resistance, and offers patient-specific cancer progression and evidence-based personalized treatment plans, enabling users to proactively adapt treatment before it becomes ineffective.

Stamp Free Ltd. operates as a digital postage stamp company.

Exogene is a biotechnology company focused on advancing T-cell receptor (TCR)-based cancer immunotherapies for solid tumors. By integrating deep learning with high-throughput TCR-antigen screening, Exogene aims to efficiently identify new tumor targets that are common among cancer patients. The company is developing a computational platform designed to discover effective and safe TCRs against these targets, facilitating their therapeutic application. This innovative approach allows for the rapid and cost-effective development of TCR-based immunotherapies, ultimately supporting healthcare providers in creating cell therapies that enhance the immune system's ability to combat cancer.